Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

The Pharmaceutical Care Management Association, which represents PBM's, called the FTC report baseless and "without ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

UnitedHealth shares a quarterly report for the first time since the death of insurance unit leader Brian Thompson. A look at ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

The time is right for PBM reform, but the American people might be better served if Congress goes back to the drawing board ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Congress missed a chance at PBM reforms.